Alzheimer disease therapy—moving from amyloid-β to tau (original) (raw)
Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science256, 184–185 (1992). ArticleCASPubMed Google Scholar
Ferreira, S. T. & Klein, W. L. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem.96, 529–543 (2011). ArticleCASPubMedPubMed Central Google Scholar
Giacobini, E. & Becker, R. E. One hundred years after discovery of Alzheimer's disease. A turning point for therapy? J. Alzheimers Dis.12, 37–52 (2007). ArticleCASPubMed Google Scholar
Becker, R. E. & Greig, N. H. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr. Alzheimer Res.7, 27–35 (2010). Article Google Scholar
Becker, R. E., Greig, H. H. & Giacobini, E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J. Alzheimers Dis.15, 303–325 (2008). ArticlePubMedPubMed Central Google Scholar
Becker, R. E. & Greig, H. H. Increasing the success rate for Alzheimer's disease drug discovery and development. Expert Opin. Drug Discov.4, 367–370 (2012). ArticleCAS Google Scholar
Hardy, J. Testing times for the “amyloid cascade hypothesis”. Neurobiol. Aging6, 1073–1074 (2002). Article Google Scholar
Hardy, J. Alzheimer disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis.9, 151–153 (2006). ArticleCASPubMed Google Scholar
Xia, W., Wong, S. T., Hanlon, E. & Morin, P. γ-Secretase modulator in Alzheimer's disease: shifting the end. J. Alzheimers Dis.31, 685–696 (2012). ArticleCASPubMed Google Scholar
Green, R. C. et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA302, 2557–2564 (2009). ArticleCASPubMedPubMed Central Google Scholar
Henley, D. B., May, P. C., Dean, R. A. & Siemers, E. R. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Exp. Opin. Pharmacother.10, 1657–1674 (2009). ArticleCAS Google Scholar
Eli Lilly and Company. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials. Eli Lilly and Company[online], (2010).
Coric, V. et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol.69, 1430–1440 (2012). ArticlePubMed Google Scholar
Atwal, J. K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med.3, 84ra43 (2011). ArticlePubMedCAS Google Scholar
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Dodel, R. et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomized, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol.12, 233–243 (2013). ArticleCASPubMedPubMed Central Google Scholar
Buttini, M. et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci.40, 9096–9101 (2005). ArticleCAS Google Scholar
Gilman, S. M., Koller, M. & Black, R. S. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64, 1553–1562 (2005). ArticleCASPubMed Google Scholar
Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol.120, 369–384 (2010). ArticleCASPubMed Google Scholar
Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6, 916–919 (2000). ArticleCASPubMed Google Scholar
Rinne, J. O. et al. 11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol.4, 363–372 (2010). ArticleCAS Google Scholar
Blennow, K. et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarkers levels in patients with mild to moderate Alzheimer disease. Arch. Neurol.69, 1002–1010 (2012). ArticlePubMed Google Scholar
Business Wire. Pfizer announces topline results of first of four studies in bapineuzumab phase 3 program. Business Wire[online], (2012).
Samadi, H. & Sultzer, D. Solanezumab for Alzheimer's disease. Expert Opin. Biol. Ther.11, 787–798 (2011). ArticleCASPubMed Google Scholar
Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci.5, 452–457 (2002). ArticleCASPubMed Google Scholar
Eli Lilly and Company. Lilly announces detailed results of phase 3 Solanezumab EXPEDITIONS studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS). Eli Lilly and Company[online], (2012).
Tariot, P. N. Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Alzheimer Dis. Assoc. Disord.15 (Suppl. 1), S26–S33 (2001). ArticleCASPubMed Google Scholar
Giacobini, E. In The Brain Cholinergic System (eds Giacobini, E. & Pepeu, G. C.) 235–264 (Informa HealthCare, 2006). Book Google Scholar
Mullane, K. & Williams, M. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond? Biochem. Pharmacol.85, 289–305 (2013). ArticleCASPubMed Google Scholar
Aisen, P. S. et al. Tramiprosate in mild-to-moderate Alzheimer's disease—a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci.7, 102–111 (2011). ArticleCASPubMedPubMed Central Google Scholar
Lannfelt, L. et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol.9, 779–786 (2008). ArticleCAS Google Scholar
Salloway, S. et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer Disease. Neurology77, 1253–1262 (2011). ArticleCASPubMedPubMed Central Google Scholar
Walker, J. R. et al. Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. J. Neurosci.33, 2457–2464 (2013). ArticleCASPubMedPubMed Central Google Scholar
Arriagada, P. V., Growdon, J. H., Hedley-White, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology42, 631–639 (1992). ArticleCASPubMed Google Scholar
Giannakopoulos, P. et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology60, 1495–1500 (2003). ArticleCASPubMed Google Scholar
Gold, G. et al. Clinical validity of Aβ-protein deposition staging in brain aging and Alzheimer disease. J. Neuropathol. Exp. Neurol.60, 946–952 (2001). ArticleCASPubMed Google Scholar
Gold, G. et al. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol.99, 579–582 (2000). ArticleCASPubMed Google Scholar
Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol.30, 572–580 (1991). ArticleCASPubMed Google Scholar
Pievani, M., de Haan, W., Wu, T., Seeley, W. W. & Frisoni, G. B. Functional network disruption in degenerative dementias. Lancet Neurol.10, 829–843 (2011). ArticlePubMedPubMed Central Google Scholar
Desikan, R. S. et al. Amyloid-β-associated clinical decline occurs only in the presence of elevated P-tau. Arch. Neurol.69, 700–713 (2012). Article Google Scholar
Corrada, M. M., Berlau, D. & Kawas, C. H. A population-based clinicopathological study in the oldest-old: the 90+ Study. Curr. Alzheimer Res.9, 709–716 (2012). ArticleCASPubMedPubMed Central Google Scholar
Balasubramanian, A. B. et al. Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia. Neurol.79, 915–921 (2012). Article Google Scholar
Villemagne, V. L. et al. Amyloid-β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective study. Lancet Neurol.12, 357–367 (2013). ArticleCASPubMed Google Scholar
Doré, V. et al. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer's disease. JAMA Neurol.27, 1–9 (2013). Google Scholar
Marchant, N. L. et al. The aging brain and cognition: contribution of vascular injury and Aβ to mild cognitive dysfunction. JAMA Neurol.70, 488–495 (2013). ArticlePubMedPubMed Central Google Scholar
Wirth, M. et al. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J. Neurosci.33, 5553–5556 (2013). ArticleCASPubMedPubMed Central Google Scholar
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell. Biol.8, 101–112 (2007). ArticleCASPubMed Google Scholar
Hardy, J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr. Alzheimer Res.3, 71–73 (2006). ArticleCASPubMed Google Scholar
Ittner, L. M. & Götz, J. Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci.12, 65–72 (2011). ArticleCASPubMed Google Scholar
Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov.10, 698–712 (2011). ArticleCASPubMed Google Scholar
Grundke-Iqbal, K. et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA83, 4913–4917 (1986). ArticleCASPubMedPubMed Central Google Scholar
Braak, H., Braak, E., Grundke-Iqbal, I. & Iqbal, K. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci. Lett.65, 351–355 (1986). ArticleCASPubMed Google Scholar
Khatoon, S., Grundke-Iqbal, I. & Iqbal, K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem.59, 750–753 (1992). ArticleCASPubMed Google Scholar
Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA98, 6923–6928 (2001). ArticleCASPubMedPubMed Central Google Scholar
Wang, J. Z., Grundke-Iqbal, I. & Iqbal, K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci.25, 59–68 (2007). ArticlePubMedPubMed Central Google Scholar
Bancher, C. et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res.16, 90–99 (1989). Article Google Scholar
Handoko, M. et al. Correlations of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol.70, 594–599 (2013). ArticlePubMedPubMed Central Google Scholar
Ashe, K. H. & Zahs, K. R. Probing the biology of Alzheimer's disease in mice. Neuron10, 631–645 (2010). ArticleCAS Google Scholar
Oddo, S. et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic plaques and tangles. J. Biol. Chem.281, 39413–39423 (2006). ArticleCASPubMed Google Scholar
Oddo, S., Billings, J., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron43, 321–332 (2004). ArticleCASPubMed Google Scholar
Nagy, Z. et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia6, 21–31 (1995). CASPubMed Google Scholar
Robertson, E. D. et al. Reducing endogenous tau ameliorates amyloid-β-induced deficits in an Alzheimer's disease mouse model. Science316, 750–754 (2007). ArticleCAS Google Scholar
Rosenmann, H. et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol.63, 1459–1467 (2006). ArticlePubMed Google Scholar
Asuni, A. A., Boutajangout, A., Quartermain, D. & Sigurdsson, E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse reduces brain pathology with associated functional improvement. J. Neurosci.27, 9115–9129 (2007). ArticleCASPubMedPubMed Central Google Scholar
Novak, M. Tau vaccine: active immunization with a misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement.5, P93 (2009). Article Google Scholar
Bi, M., Ittner, A., Ke, J. D., Götz, J. & Ittner, L. M. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE6, 12–18 (2012). Google Scholar
Chai, X. et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J. Biol. Chem.286, 34457–34467 (2012). ArticleCAS Google Scholar
Troquier, L. et al. Targeting phospho-Ser422 by active tau immunotherapy in the THY Tau22 mouse model: a suitable therapeutic approach. Curr. Alz. Res.9, 397–405 (2012). Article Google Scholar
Novak, M. Tau transgenic rat model and response to tau vaccine. Alzheimers Dement.6, S118 (2010). Article Google Scholar
Theunis, C. et al. Protein tau, target for immunotherapy: preclinical evaluation in transgenic mice [abstract]. Neurodegener. Dis.8, (Suppl. 1, 2011).
Krishnamurthy, P., Gonzales, V., Rajamohamedsait, H. B. & Sigurdsson, E. Immunization with a pseudo-phosphorylated tau epitope clears tau pathology in a mouse model [abstract]. Alzheimers Dement.7, S481–S482 (2011). Article Google Scholar
Yoshiyama, Y., Lee, V. M. & Trojanowski, J. Q. Therapeutic strategies for tau mediated neurodegeneration. J. Neurol. Neurosurg. Psychiatry84, 784–795 (2013). ArticlePubMed Google Scholar
Hochgräfe, K., Sydow, A. & Mandelkow, E. M. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of tau pathology. FEBS J.280, 4371–4381 (2013). ArticlePubMedCAS Google Scholar
Zhang, B. et al. Microtubule-binding drugs offset tau sequestration by stabilizing mictrotubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA102, 227–231 (2005). ArticleCASPubMed Google Scholar
Gold, M. et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr. Dis. Treat.8, 85–93 (2012). CASPubMedPubMed Central Google Scholar
Jouroukhin, Y. et al. NAP (davenutide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis.56, 79–94 (2013). ArticleCASPubMed Google Scholar
Götz, J., Ittner, A. & Ittner, L. Tau-targeted treatment strategies in Alzheimer's disease. Br. J. Pharm.165, 1246–1259 (2012). ArticleCAS Google Scholar
Wischick, C. & Staff, R. Challenges in the conduct of disesase-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitory therapy. J. Nutr. Health Aging13, 367–369 (2009). Article Google Scholar
Macdonald, A. et al. A feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriat. Psychiatry23, 704–711 (2008). Article Google Scholar
Tariot, P. N. et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry68, 853–861 (2011). ArticleCASPubMedPubMed Central Google Scholar
Hu, J. P. et al. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res. Bull.30, 194–200 (2011). ArticleCAS Google Scholar
Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun.120, 885–890 (1984). ArticleCASPubMed Google Scholar